Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.57 |
| ▸ | CPB1 | P15086 | 1/20 | 0.57 |
| ▸ | CPA3 | P15088 | 1/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.57 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | MMP12 | P39900 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8399603 | 0.92 | CPA3 (0.66) | CPA1CPB1CPA3CPB2MMP12 | |
| SCHEMBL7354310 | 0.92 | CPA3 (0.66) | CPA1CPB1CPA3CPB2MMP12 | |
| SCHEMBL7289839 | 0.92 | CPA3 (0.66) | CPA1CPB1CPA3CPB2MMP12 | |
| SCHEMBL7346268 | 0.87 | CPA1 (0.55) | CPA1CPB1CPA3CPB2MMEL1 | |
| SCHEMBL7346272 | 0.87 | CPA1 (0.55) | CPA1CPB1CPA3CPB2MMEL1 | |
| SCHEMBL2571746 | 0.84 | CPA1 (0.56) | CPA1CPB1CPA3CPB2 | |
| SCHEMBL1912582 | 0.84 | MMEL1 (0.60) | CPA1CPB1CPA3CPB2MMEL1 | |
| SCHEMBL3698369 | 0.83 | CA2 (0.49) | PPARGPPARACYP1A2 | |
| SCHEMBL23501480 | 0.83 | MME (0.52) | MME | |
| SCHEMBL21811160 | 0.81 | CYP1A2 (0.59) | CPA1CPB1CPA3CPB2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2640689-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CPA1 106/4885CPB1 911/4885CPA3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.